CCA
STSA

Column Capital Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Column Capital Advisors’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-162
Closed -$1K – 744
2021
Q1 		$1K Buy
+162
New +$981 ﹤0.01% 699

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Capital Advisors's STSA Position: Q2 2021 in Review

Column Capital Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2021, closing a stake of 162 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in STSA in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 60 funds tracked by Wall St. Rank hold STSA as of Q2 2021.

  • Column Capital Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Column Capital Advisors sold 162 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $1K.
  • Column Capital Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Column Capital Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Column Capital Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.